Live data · NADAC + Part D CY24 · reviewed daily

Ergotamine and Caffeine (Cafergot)

Ergotamine and Caffeine is indicated for the acute treatment of migraine headache with or without aura.

First FDA approval1983-10-30
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
—/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
—
Across all dosage forms in distribution.
Highest NADAC
—
Range is tight.
Plans with PA
77 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Ergotamine and Caffeine used for?

Ergotamine and Caffeine is indicated for the acute treatment of migraine headache with or without aura.

Is there a generic for Ergotamine and Caffeine?

Yes. 2 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Ergotamine and Caffeine?

NADAC pricing data not currently available for this drug.

Is Ergotamine and Caffeine on the FDA shortage list?

No. Ergotamine and Caffeine is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.